Generic Daklinza Deal Sets Precedent In HCV Drug Licensing
This article was originally published in Scrip
The licensing agreement announced on Nov. 23 by the Medicines Patent Pool and Bristol-Myers Squibb, under which generics firms will be able to manufacture their own versions of the firm's hepatitis C drug daclatasvir for sale in more than a hundred lower-income countries, breaks new ground in several different ways.
You may also be interested in...
Trademark disputes continue unabated in Indian courts, this time involving generic versions of Bristol-Myers Squibb's hepatitis C therapy, Daklinza (daclatasvir) marketed by the local firms Cadila Healthcare and Hetero.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.